Skip to main content
NCBI home page
Heart logoLink to Heart
. 1998 Oct;80(4):338–340. doi: 10.1136/hrt.80.4.338

Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries

A Dacosta 1, B Tardy-Poncet 1, K Isaaz 1, A Cerisier 1, P Mismetti 1, S Simitsidis 1, J Reynaud 1, B Tardy 1, M Piot 1, H Decousus 1, D Guyotat 1
PMCID: PMC1728822  PMID: 9875108

Abstract

Objective—To investigate the role of activated protein C resistance (APCR, factor V Leiden) in coronary artery thrombosis.
Methods—The prevalence of APCR and of congenital deficiencies of antithrombin III, protein C, protein S, plasminogen, and factor XII was investigated in adult patients under 45 years of age with acute myocardial infarction. The results were compared with those of a group of 53 age and sex matched control subjects.
Results—Among 75 patients under the age of 45 years who were admitted from November 1994 to April 1996 for acute myocardial infarction, 22 (29.3%) had normal coronary arteriography (group I) and 53 (70.7%) had significant coronary artery disease (group II). Inherited thrombophilia was more often found in group I (4/22, 18.2%) than in group II (4/53, 7.5%) but the difference was not significant (F test: p = 0.22). The prevalence of APCR was 9.1% (2/22) in group I, 3.8% (2/53) in group 2 (p  = 0.57), and 3.8% (2/53) in the normal control group (p = 0.57).
Conclusions—The prevalence of congenital thrombophilias, including APCR, does not seem to be increased in young patients with myocardial infarction and normal coronary angiograms, compared with young patients with coronary atherosclerosis and with normal control subjects. However, the statistical power of the study is too low to detect a significant difference and these results are published to allow a meta-analysis of this problem in the future.

 Keywords: myocardial infarction;  factor V Leiden;  coagulation factors;  inherited thrombophilia

Full Text

The Full Text of this article is available as a PDF (91.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alpert J. S. Myocardial infarction with angiographically normal coronary arteries. Arch Intern Med. 1994 Feb 14;154(3):265–269. [PubMed] [Google Scholar]
  2. Ardissino D., Peyvandi F., Merlini P. A., Colombi E., Mannucci P. M. Factor V (Arg 506-->Gln) mutation in young survivors of myocardial infarction. Thromb Haemost. 1996 May;75(5):701–702. [PubMed] [Google Scholar]
  3. Bauer K. A. Hypercoagulability--a new cofactor in the protein C anticoagulant pathway. N Engl J Med. 1994 Feb 24;330(8):566–567. doi: 10.1056/NEJM199402243300810. [DOI] [PubMed] [Google Scholar]
  4. Bloemenkamp K. W., Rosendaal F. R., Helmerhorst F. M., Büller H. R., Vandenbroucke J. P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995 Dec 16;346(8990):1593–1596. doi: 10.1016/s0140-6736(95)91929-5. [DOI] [PubMed] [Google Scholar]
  5. Brecker S. J., Stevenson R. N., Roberts R., Uthayakumar S., Timmis A. D., Balcon R. Acute myocardial infarction in patients with normal coronary arteries. BMJ. 1993 Nov 13;307(6914):1255–1256. doi: 10.1136/bmj.307.6914.1255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dacosta A., Guy J. M., Rousset H., Cerisier A., Gonthier R., Dall'Acqua T., Bouchou K., Lamaud M., Verneyre H. Infarctus indolore au cours du syndrome des antiphospholipides. Arch Mal Coeur Vaiss. 1993 Dec;86(12):1773–1775. [PubMed] [Google Scholar]
  7. Denson K. W., Reed S. V., Haddon M. E. Validity of the INR system for patients with liver impairment. Thromb Haemost. 1995 Jan;73(1):162–162. [PubMed] [Google Scholar]
  8. Desmarais S., de Moerloose P., Reber G., Minazio P., Perrier A., Bounameaux H. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet. 1996 May 18;347(9012):1374–1375. doi: 10.1016/s0140-6736(96)91013-2. [DOI] [PubMed] [Google Scholar]
  9. Emmerich J., Poirier O., Evans A., Marques-Vidal P., Arveiler D., Luc G., Aiach M., Cambien F. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance. Lancet. 1995 Feb 4;345(8945):321–321. [PubMed] [Google Scholar]
  10. Hajjar K. A. Factor V Leiden--an unselfish gene? N Engl J Med. 1994 Dec 8;331(23):1585–1587. doi: 10.1056/NEJM199412083312310. [DOI] [PubMed] [Google Scholar]
  11. Holm J., Zöller B., Svensson P. J., Berntorp E., Erhardt L., Dahlbäck B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet. 1994 Oct 1;344(8927):952–953. doi: 10.1016/s0140-6736(94)92302-7. [DOI] [PubMed] [Google Scholar]
  12. Kontula K., Ylikorkala A., Miettinen H., Vuorio A., Kauppinen-Mäkelin R., Hämäläinen L., Palomäki H., Kaste M. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost. 1995 Apr;73(4):558–560. [PubMed] [Google Scholar]
  13. Koster T., Rosendaal F. R., de Ronde H., Briët E., Vandenbroucke J. P., Bertina R. M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993 Dec 18;342(8886-8887):1503–1506. doi: 10.1016/s0140-6736(05)80081-9. [DOI] [PubMed] [Google Scholar]
  14. Kyriakidis M., Androulakis A., Triposkiadis F., Tentolouris K., Vardinoyannis V., Copsari C., Iliopoulou E., Gialafos J., Bossinakou I., Toutouzas P. Lack of a thrombotic tendency in patients with acute myocardial infarction and angiographically normal coronary arteries. Cardiology. 1995;86(1):22–24. doi: 10.1159/000176825. [DOI] [PubMed] [Google Scholar]
  15. Lindblad B., Svensson P. J., Dahlbäck B. Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C. Lancet. 1994 Apr 9;343(8902):917–917. doi: 10.1016/s0140-6736(94)90035-3. [DOI] [PubMed] [Google Scholar]
  16. Mandel H., Brenner B., Berant M., Rosenberg N., Lanir N., Jakobs C., Fowler B., Seligsohn U. Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis. N Engl J Med. 1996 Mar 21;334(12):763–768. doi: 10.1056/NEJM199603213341204. [DOI] [PubMed] [Google Scholar]
  17. März W., Seydewitz H., Winkelmann B., Chen M., Nauck M., Witt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet. 1995 Feb 25;345(8948):526–526. [PubMed] [Google Scholar]
  18. Rees D. C., Cox M., Clegg J. B. World distribution of factor V Leiden. Lancet. 1995 Oct 28;346(8983):1133–1134. doi: 10.1016/s0140-6736(95)91803-5. [DOI] [PubMed] [Google Scholar]
  19. Ridker P. M., Hennekens C. H., Lindpaintner K., Stampfer M. J., Eisenberg P. R., Miletich J. P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995 Apr 6;332(14):912–917. doi: 10.1056/NEJM199504063321403. [DOI] [PubMed] [Google Scholar]
  20. Ridker P. M., Miletich J. P., Stampfer M. J., Goldhaber S. Z., Lindpaintner K., Hennekens C. H. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995 Nov 15;92(10):2800–2802. doi: 10.1161/01.cir.92.10.2800. [DOI] [PubMed] [Google Scholar]
  21. Svensson P. J., Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994 Feb 24;330(8):517–522. doi: 10.1056/NEJM199402243300801. [DOI] [PubMed] [Google Scholar]
  22. Tuddenham E. G. Thrombophilia: the new factor is old factor V. Lancet. 1994 Jun 18;343(8912):1515–1516. doi: 10.1016/s0140-6736(94)92932-7. [DOI] [PubMed] [Google Scholar]
  23. Vandenbroucke J. P., Koster T., Briët E., Reitsma P. H., Bertina R. M., Rosendaal F. R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994 Nov 26;344(8935):1453–1457. doi: 10.1016/s0140-6736(94)90286-0. [DOI] [PubMed] [Google Scholar]
  24. Voorberg J., Roelse J., Koopman R., Büller H., Berends F., ten Cate J. W., Mertens K., van Mourik J. A. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994 Jun 18;343(8912):1535–1536. doi: 10.1016/s0140-6736(94)92939-4. [DOI] [PubMed] [Google Scholar]
  25. Zöller B., Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994 Jun 18;343(8912):1536–1538. doi: 10.1016/s0140-6736(94)92940-8. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES